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Chen and collaborators propose RANKL blockade for 
the treatment and prevention of aggressive RANKL-
overexpressing osteosarcoma (OS) in humans. Here we 
comment the main findings, putative applications and 
concerns. 
OS is the most common primary bone cancer, which 
occurs primarily in children and adolescents, severely 
affecting survivors’ quality of life. Current treatment for 
newly diagnosed OS includes three main components: 
preoperative chemotherapy, surgical resection, and 
postoperative chemotherapy (1). This strategy has improved 
the outcome of patients with localized OS. However, patients 
with advanced, metastatic, and recurrent OSs continue to 
experience a quite poor prognosis. After aggressive treatment 
with both surgery and chemotherapy, the 5-year survival 
rate for OS patients with localized disease is about 65%, 
whereas it is less than 20% for patients with metastases. 
The use of adjuvant chemotherapy provides no survival 
advantage for patients with pulmonary metastases (2). So 
that, it is of particular importance to develop molecularly 
targeted therapy to treat patients with this metastatic bone 
malignancy, on the basis of in-depth understanding of 
signaling mechanisms involved in OS tumorigenesis.
Bone growth and turnover are regulated by receptor-
activator of nuclear kappa B (RANK) and its ligand (RANKL). 
RANKL is expressed by cells of the osteoblast lineage in 
the bone stroma as well as osteocytes; it binds its cognate 
receptor, RANK, expressed on osteoclasts and osteoclast 
precursors and induces osteoclastogenesis. Osteoprotegerin 
(OPG) is a soluble decoy receptor for RANKL which 
acts as a dominant negative of the pathway. During bone 
metastasis, tumor cells that invade the bone secrete factors 
that stimulate the production of RANKL by stromal cells 
and osteoblasts. RANKL-RANK signaling in osteoclast 
precursors triggers osteoclastogenesis and bone destruction, 
which in turn releases growth factors to attract and stimulate 
tumor cell growth, propagating a “vicious cycle” between 
bone destruction and tumor expansion. Multiple clinical trials 
demonstrate that Denosumab, a fully human monoclonal 
antibody specific to RANKL, prevents and attenuates bone 
metastasis by interfering with this cycle (3).
In this work Chen and colleagues have generated a 
series of genetically engineered mouse models (GEMMs) 
combining deletions of retinoblastoma (RB), tumor protein 
p53 (TP53) and Prkar1a. The group of Dr. Khokha had 
previously shown that Prkar1a acts as a tumor suppressor 
in OS pathogenesis, and its deletion drives RANKL 
overexpression during OS tumorigenesis (4). Different 
combination of deletions of these three genes generated 
different grade of aggressiveness in OS. The most aggressive 
tumors showed high levels of RANKL and low expression 
of RANK in tumor cells; therefore RANKL was postulated 
to play a critical role in aggressive osteosarcomagenesis. 
To test this hypothesis the authors used an additional 
mouse model MOTO GEMM, in which SV40 T antigen 
oncoprotein binds and inactivates RB and p53. This model 
develops aggressive OS similar to those developed after 
Prkar1a deletion. From this GEMM a new model MOTO-
Rankl−⁄− was generated and compared with its control 
MOTO-Rankl+/+. The absence of RANKL caused a marked 
suppression of OS development, indicating that RANKL 
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is a critical protein for OS tumorigenesis. RANK deletion 
in the osteoblast lineage, where the osteoblastic RANKL 
expression remains intact, exerts a negligible effect on 
OS; while RANK deletion in osteoclast, led to delayed 
tumor initiation, prolonged life span, and fewer metastatic 
nodules in the lung. These data indicate that blockage of 
RANK/RANKL would have an indirect effect on tumor 
development through of inhibition of osteoclasts. Moreover, 
Chen et al. demonstrated that PTEN is modulated by 
RANKL-RANK signaling through NF-kB in OS cells 
supporting a direct effect of RANK signaling blockage in 
OS tumor development. The therapeutic benefit of RANKL 
inhibition in OS was tested pharmacologically using 
RANK-Fc, which binds RANKL and inhibits the pathway. 
RANK-Fc administered immediately after detection of 
the tumor, prolonged and extended survival and decreased 
lung metastasis. RANK-Fc administration before tumors 
detection blocked tumor development. However, upon 
termination of RANK, osteoclastogenesis was reinitiated 
and tumors developed implying that treatment cannot be 
interrupted.
In view of these encouraging results the authors suggest 
the use of RANKL inhibitors, such as Denosumab for the 
treatment of aggressive RANKL-overexpressing OS and 
prevention of heritable OS in children bearing germline 
mutations in the TP53 and RB genes. However, it is 
important to take into account that a fine regulation of 
RANK pathway is essential for normal bone physiology, 
which is particularly critical in children and adolescents who 
are the ones suffering OS. The effect of Denosumab on 
the developing skeleton has not been established. RANKL 
signaling blockage could provoke severe growth defects in 
this age. As shown in this manuscript long-term RANK-Fc 
treatment prevented tumor formation, but also increased 
bone density, indicative of osteopetrosis. Osteopetrosis 
is a bone disease that makes bones abnormally dense and 
prone to breakage. Thus, using Denosumab in this age 
group could lead to undesired side effects, more aggravated 
than those observed in adults. The optimal use and long-
term effects of Denosumab in the young population 
primarily affected by OS needs to be defined. Denosumab 
brings hope for patients with OS, but side effects should 
be carefully evaluated, doses readjusted and a personalized 
exhaustive control should be kept.
Moreover, it has been recently published that although 
RANKL expression was observed in 68% of human OS 
using IHC, the staining intensity was relatively low and only 
37% of samples exhibited equal or mayor 10% RANKL 
positive tumor cells; moreover, RANK expression was not 
observed in OS tumor cells (5). These data cast doubt on 
the effectiveness of RANKL blockage in human OS. The 
intensity and frequency of RANKL and RANK staining 
in OS samples were substantially lower than that observed 
in giant cell tumor of bone samples, in which RANKL 
expression and the therapeutic efficacy of Denosumab have 
recently been reported (6). All results showed in the paper 
were based in mouse models that exhibited OS with high 
expression of RANKL. Therefore, before supplying this 
treatment in humans the expression of RANKL should 
be assessed in each case, which leads to a personalized 
treatment again. It is possible that only tumors showing 
high expression of RANKL would be susceptible to be 
treated with Denosumab. The anti-RANKL therapy 
may be especially important for protection against bone 
pathologies driven by RANKL-expressing OS tumor cells 
able to mediate an osteoclastic response (5). However, the 
absence of RANK expression in primary human OS cells 
suggests that an autocrine RANKL/RANK signaling in 
human OS tumor cells is not operative, and that the anti-
RANKL therapy would not directly affect the tumor cells. 
This seems a different scenario to that observed in breast 
cancer where RANK expression on tumor cells is found in 
a significant percentage of patients (7,8). In this setting, the 
preventive and therapeutic benefit of RANKL inhibition 
is explained by its direct effects on RANK-expressing 
tumor cells. RANK-Fc treatment reduces proliferation 
and survival of mammary epithelial cells in early stages 
of tumorigenesis and causes tumor cell differentiation in 
aggressive adenocarcinomas (9,10).
Denosumab is now to be tested in a phase 2 trial 
in patients with relapsed or refractory OS (https://
clinicaltrials.gov/ct2/show/NCT02470091) and compared 
to historical Children’s Oncology Group experience. This 
trial will reveal if the use of this antibody could improve 
the prognosis of this disease, either indirectly by blocking 
osteoclastogenesis, or directly, impacting tumor cells. 
Results from this clinical trial will shed light into the risk-
benefit balance of Denosumab as a treatment option in OS. 
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